Subtitle
Dose-escalated proton therapy with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer: a phase II trial.
Subtitle
Dose-escalated proton therapy with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer: a phase II trial.
Proto therapy Time
June 2022
Executive summary
Fifteen patients received proton therapy delivered 40.5 GyRBE in 18 fractions to the gross disease and elective nodal volumes followed by 22.5 GyRBE as a 10-fraction boost to the gross disease for a cumulative dose of 63 GyRBE over 28 fractions. The 1-year OS rate was 47%. One patient experienced grade 3 nausea requiring cessation of capecitabine, which ultimately resolved by treatment completion. The primary objective of 1-year OS of 75% for this phase II trial was not reached.
Key content topics
Top cancer treatments
Related contents
Proton Therapy Publication
April 2024
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
Proton Therapy Publication
November 2023
Proton Therapy Mediates Dose Reductions to Brain Structures Associated with Cognition in Children with Medulloblastoma.
Proton Therapy Publication
October 2023
Radiation-induced skin and heart toxicity in patients with breast cancer treated with adjuvant proton radiotherapy: a comparison with photon radiotherapy.
Proton Therapy Publication
September 2023
Ultra-High Dose-Rate Proton FLASH Improves Tumor Control.
Proton Therapy Publication
June 2023
The current status of FLASH particle therapy: a systematic review.
Proton Therapy Publication
May and June 2023
ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.
Proton Therapy Publication
April 2023
Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
Proton Therapy Publication
March 2023
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Proton Therapy Publication
November 2022
A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.